1. Home
  2. WES vs UTHR Comparison

WES vs UTHR Comparison

Compare WES & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Midstream Partners LP Common Units Representing Limited Partner Interests

WES

Western Midstream Partners LP Common Units Representing Limited Partner Interests

HOLD

Current Price

$40.05

Market Cap

15.0B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WES
UTHR
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0B
20.3B
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
WES
UTHR
Price
$40.05
$488.92
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$41.20
$495.08
AVG Volume (30 Days)
1.6M
424.3K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
9.10%
N/A
EPS Growth
N/A
16.08
EPS
3.38
26.38
Revenue
$3,740,425,000.00
$3,128,400,000.00
Revenue This Year
$8.40
$13.64
Revenue Next Year
$6.96
$5.78
P/E Ratio
$11.83
$18.55
Revenue Growth
5.81
13.50
52 Week Low
$33.60
$266.98
52 Week High
$43.33
$492.62

Technical Indicators

Market Signals
Indicator
WES
UTHR
Relative Strength Index (RSI) 60.21 68.10
Support Level $38.79 $470.13
Resistance Level $39.73 $492.62
Average True Range (ATR) 0.62 10.72
MACD 0.09 -0.53
Stochastic Oscillator 67.52 89.55

Price Performance

Historical Comparison
WES
UTHR

About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests

Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: